Taysha Gene Therapies, Inc.
Financials
Valuation Metrics
Taysha Gene Therapies, Inc.'s Market Cap is $1.30B. At end of 2025 it was $1.76B. Ranked #2243 of 3,118 in US market (top 72%), #892 of 1,474 on NASDAQ (top 61%), #164 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.30B | US#2,243/3,118 Sec#164/265 |
| Revenue | $5M | US#2,819/3,118 Sec#176/265 |
| Net Income | $-150M | US—/3,118 Sec—/265 |
| Total Assets | $470M | US#2,786/3,118 Sec#170/265 |
| Net Assets | $387M | US#2,378/3,118 Sec#135/265 |
| Employees | 99 | US#2,619/3,118 Sec#179/265 |
| Value | ||
| P/B | 3.35x | US#1,926/3,118 Sec#109/265 |
| P/S | 237.25x | US#2,960/3,118 Sec#187/265 |
| FCF Yield | -10.44% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -38.64% | US#2,614/3,118 Sec#135/265 |
| ROA | -31.81% | US#2,889/3,118 Sec#163/265 |
| Op. Margin | -2798.45% | US#2,816/3,118 Sec#169/265 |
| Revenue Growth | -32.11% | US#2,670/3,118 Sec#153/265 |
| Financial Health | ||
| Debt Ratio | 21.48% | US#242/3,118 Sec#82/265 |
| Total Debt | $56M | US#2,579/3,118 Sec#151/265 |
| FCF | $-136M | US#2,697/3,118 Sec#171/265 |
| Cash | $455M | US#1,129/3,118 Sec#62/265 |
| Current Ratio | 17.76x | US#132/3,118 Sec#34/265 |
| Performance | ||
| 1Y Return | -19.66% | US#2,316/3,118 Sec#181/265 |
| 1M Return | -13.93% | US#2,673/3,118 Sec#207/265 |
| From 52W High | -45.41% | US#2,461/3,118 Sec#178/265 |
| 1Y MDD | -49.71% | US#2,387/3,118 Sec#160/265 |
| Trading | ||
| Volume | 1,627,284 shares | US#1,401/3,118 Sec#131/265 |
| Trading Value | $7M | US#2,643/3,118 Sec#212/265 |
| Per Share | ||
| EPS | $-0.46 | US—/3,118 Sec—/265 |
| BPS | $1.19 | US#2,663/3,118 Sec#197/265 |
Company Info
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.